The Role of Human Immunodeficiency Virus in Influenza- and Respiratory Syncytial Virus-associated Hospitalizations in South African Children, 2011-2016.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
15 02 2019
Historique:
received: 14 05 2018
accepted: 28 06 2018
pubmed: 3 7 2018
medline: 9 4 2020
entrez: 3 7 2018
Statut: ppublish

Résumé

Data describing influenza- or respiratory syncytial virus (RSV)-associated hospitalized illness in children aged <5 years in Africa are limited. During 2011-2016, we conducted surveillance for severe respiratory illness (SRI) in children aged <5 years in 3 South African hospitals. Nasopharyngeal aspirates were tested for influenza and RSV using real-time reverse transcription polymerase chain reaction. We estimated rates of influenza- and RSV-associated hospitalized SRI by human immunodeficiency virus (HIV) status and compared children who tested positive for influenza vs RSV using multivariable penalized logistic regression. Among 3650 hospitalized children, 203 (5.6%) tested positive for influenza viruses, 874 (23.9%) for RSV, and 19 (0.5%) for both. The median age of children hospitalized with influenza was 13.9 months vs 4.4 months for RSV (P < .01). Annual influenza-associated hospitalization rates per 100000 were highest among infants aged 6-11 months (545; 95% confidence interval [CI], 409-703), while RSV-associated hospitalization rates were highest in infants aged 0-2 months (6593; 95% CI, 5947-7217). HIV exposure was associated with increased incidence of influenza- and RSV-associated hospitalization in infants aged 0-5 months, with relative risk (RR) 2.2 (95% CI, 1.4-3.4) and 1.4 (95% CI, 1.3-1.6), respectively. HIV infection was associated with increased incidence of influenza- and RSV-associated hospitalization in all age groups; RR 2.7 (95% CI, 2.0-3.5) and 3.8 (95% CI, 3.1-4.8), respectively. Influenza- and RSV-associated hospitalizations are common among South African infants. HIV infection and HIV exposure in infants increase risk of influenza- and RSV-associated hospitalization.

Sections du résumé

BACKGROUND
Data describing influenza- or respiratory syncytial virus (RSV)-associated hospitalized illness in children aged <5 years in Africa are limited.
METHODS
During 2011-2016, we conducted surveillance for severe respiratory illness (SRI) in children aged <5 years in 3 South African hospitals. Nasopharyngeal aspirates were tested for influenza and RSV using real-time reverse transcription polymerase chain reaction. We estimated rates of influenza- and RSV-associated hospitalized SRI by human immunodeficiency virus (HIV) status and compared children who tested positive for influenza vs RSV using multivariable penalized logistic regression.
RESULTS
Among 3650 hospitalized children, 203 (5.6%) tested positive for influenza viruses, 874 (23.9%) for RSV, and 19 (0.5%) for both. The median age of children hospitalized with influenza was 13.9 months vs 4.4 months for RSV (P < .01). Annual influenza-associated hospitalization rates per 100000 were highest among infants aged 6-11 months (545; 95% confidence interval [CI], 409-703), while RSV-associated hospitalization rates were highest in infants aged 0-2 months (6593; 95% CI, 5947-7217). HIV exposure was associated with increased incidence of influenza- and RSV-associated hospitalization in infants aged 0-5 months, with relative risk (RR) 2.2 (95% CI, 1.4-3.4) and 1.4 (95% CI, 1.3-1.6), respectively. HIV infection was associated with increased incidence of influenza- and RSV-associated hospitalization in all age groups; RR 2.7 (95% CI, 2.0-3.5) and 3.8 (95% CI, 3.1-4.8), respectively.
CONCLUSIONS
Influenza- and RSV-associated hospitalizations are common among South African infants. HIV infection and HIV exposure in infants increase risk of influenza- and RSV-associated hospitalization.

Identifiants

pubmed: 29961814
pii: 5046790
doi: 10.1093/cid/ciy532
pmc: PMC6432774
mid: NIHMS1006008
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

773-780

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001048
Pays : United States
Organisme : ACL HHS
ID : U01IP001048
Pays : United States

Informations de copyright

Published by Oxford University Press for the Infectious Diseases Society of America 2018.

Références

J Clin Microbiol. 2007 Aug;45(8):2460-6
pubmed: 17537936
Sci Transl Med. 2017 May 3;9(388):
pubmed: 28469033
Curr Top Microbiol Immunol. 2013;372:39-57
pubmed: 24362683
Lancet Child Adolesc Health. 2018 May;2(5):338-349
pubmed: 30169267
N Engl J Med. 2010 Apr 29;362(17):1644-6
pubmed: 20427817
Emerg Infect Dis. 2017 Jul;23(7):1124-1132
pubmed: 28628462
N Engl J Med. 2009 Feb 5;360(6):588-98
pubmed: 19196675
JAMA. 2003 Sep 24;290(12):1608-16
pubmed: 14506120
N Engl J Med. 2011 Oct 13;365(15):1406-16
pubmed: 21995388
J Infect Dis. 2013 Dec 15;208 Suppl 3:S217-26
pubmed: 24265481
PLoS One. 2014 Aug 18;9(8):e105543
pubmed: 25133576
Pediatrics. 2016 Apr;137(4):
pubmed: 27025960
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Lancet. 2011 Dec 3;378(9807):1917-30
pubmed: 22078723
BMC Infect Dis. 2014 Dec 16;14:694
pubmed: 25510622
Vaccine. 2017 Dec 15;35(50):6967-6976
pubmed: 29100706
Lancet. 2013 Apr 20;381(9875):1380-1390
pubmed: 23369797
Clin Infect Dis. 2015 May 1;60(9):1346-56
pubmed: 25645212
Pediatr Infect Dis J. 2015 Jan;34(1):66-72
pubmed: 25093972
Emerg Infect Dis. 2013 Nov;19(11):1766-74
pubmed: 24209781
PLoS Med. 2016 Mar 24;13(3):e1001977
pubmed: 27011229
Clin Infect Dis. 2018 Jan 6;66(1):95-103
pubmed: 29040527
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
Lancet Infect Dis. 2016 Sep;16(9):1026-1035
pubmed: 27261067
J Infect Dis. 2015 Dec 15;212(12):1976-87
pubmed: 26080370
PLoS One. 2009 Dec 02;4(12):e8088
pubmed: 19956576
J Infect Dis. 2012 Dec 15;206 Suppl 1:S159-65
pubmed: 23169964

Auteurs

Meredith L McMorrow (ML)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.
US Public Health Service, Rockville, Maryland.

Stefano Tempia (S)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.
Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service.

Sibongile Walaza (S)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service.
School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Florette K Treurnicht (FK)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service.

Jocelyn Moyes (J)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service.
School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Adam L Cohen (AL)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.
US Public Health Service, Rockville, Maryland.
Global Immunization Monitoring and Surveillance Team, Expanded Programme on Immunization, Department of Immunization, Vaccines and Biological, World Health Organization, Geneva.

Marthi Pretorius (M)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service.
Technical Research and Development, Novartis Pharma AG, Basel, Switzerland.

Orienka Hellferscee (O)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service.
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.

Nicole Wolter (N)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service.
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.

Anne von Gottberg (A)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service.
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.

Arthemon Nguweneza (A)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service.

Johanna M McAnerney (JM)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service.

Fathima Naby (F)

Department of Paediatrics, Pietermaritzburg Metropolitan Hospitals, University of KwaZulu-Natal.

Omphile Mekgoe (O)

Department of Paediatrics, Klerksdorp Hospital, North West Province.

Marietjie Venter (M)

Emerging Vectorborne and Respiratory Virus Program, Center for Viral Zoonoses, Department of Medical Virology, University of Pretoria.

Shabir A Madhi (SA)

Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand.
Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa.

Cheryl Cohen (C)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service.
School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH